港股異動丨上半年增收不增利 醫脈通(2192.HK)跌逾5%
格隆匯8月27日丨次新股醫脈通(2192.HK)跳空低開,現跌5.45%,報31.1港元,總市值221.8億港元。醫脈通公吿,上半年收益1.31億元(人民幣,下同),同比增長47.1%;期內溢利1964.5萬元,同比下降43.1%。不派中期息。集團大部分收益來自精準營銷解決方案,該解決方案為製藥及醫療設備公司提供數字醫療營銷服務。目前集團自主開發的醫脈通平台亦廣獲中國醫師認可,已成為最受歡迎的專業醫療平台。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.